whi p154 has been researched along with sirolimus in 2 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (50.00) | 29.6817 |
2010's | 1 (50.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Augustin, M; Davies, SP; Gao, Y; Harvey, KJ; Kovelman, R; Patel, UA; Woodward, A | 1 |
Bucki, R; El-Salem, M; Halasa, K; Kasprzycka, M; Liu, X; Marzec, M; Raghunath, PN; Wasik, MA; Wlodarski, P | 1 |
2 other study(ies) available for whi p154 and sirolimus
Article | Year |
---|---|
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
Topics: Aurora Kinases; Cluster Analysis; Drug Design; Drug Discovery; Drug Evaluation, Preclinical; ErbB Receptors; Humans; Intracellular Signaling Peptides and Proteins; MAP Kinase Kinase 4; p38 Mitogen-Activated Protein Kinases; Protein Kinase Inhibitors; Protein Kinases; Protein Serine-Threonine Kinases; Protein-Tyrosine Kinases; Receptors, Vascular Endothelial Growth Factor; Recombinant Proteins; Reproducibility of Results; Signal Transduction; Small Molecule Libraries; Structure-Activity Relationship; Syk Kinase | 2013 |
Oncogenic tyrosine kinase NPM/ALK induces activation of the rapamycin-sensitive mTOR signaling pathway.
Topics: Anaplastic Lymphoma Kinase; Animals; Blotting, Western; Cell Line; Cell Line, Tumor; Cell Proliferation; Cell Survival; Extracellular Signal-Regulated MAP Kinases; Humans; Immunohistochemistry; Lymphoma, T-Cell; Mitogen-Activated Protein Kinases; Models, Biological; Nuclear Proteins; Nucleophosmin; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Protein Kinase Inhibitors; Protein Kinases; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-akt; Quinazolines; Receptor Protein-Tyrosine Kinases; RNA, Small Interfering; Signal Transduction; Sirolimus; TOR Serine-Threonine Kinases; Transfection | 2007 |